Pluristem Therapeutics Share Price Nasdaq
Equities
Biotechnology & Medical Research
Sales 2022 | 234K 18.62M | Sales 2023 | 287K 22.84M | Capitalization | 32.98M 2.62B |
---|---|---|---|---|---|
Net income 2022 | -41M -3.26B | Net income 2023 | -28M -2.23B | EV / Sales 2022 | 58 x |
Net cash position 2022 | 26.21M 2.09B | Net cash position 2023 | 10.27M 817M | EV / Sales 2023 | 79.1 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-1.04
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.38% |
Managers | Title | Age | Since |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 31/10/06 |
Director of Finance/CFO | 40 | 30/04/13 | |
Zami Aberman
CHM | Chairman | 70 | 25/09/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 14/07/21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 10/07/23 |
Zami Aberman
CHM | Chairman | 70 | 25/09/05 |
1st Jan change | Capi. | |
---|---|---|
+2.72% | 42.75B | |
+47.70% | 41.61B | |
+11.92% | 41.34B | |
-8.83% | 26.59B | |
+7.72% | 25.49B | |
-22.52% | 18.12B | |
+30.96% | 12.24B | |
-1.73% | 11.76B | |
+9.46% | 11B |